Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In the STEP 1 and SUSTAIN 8 trials, around 40% of the weight lost was lean tissue
Selecting the most appropriate GLP-1 receptor agonist requires consideration of multiple patient-specific factors, clinical characteristics, and treatment goals
References: Ding Y, Shi Y, Guan R, et al
[5] No overdosage or toxicity has been reported with this drug
No one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial
Pharmacological progress in metabolic research models: tirzepatide's rising advantage [PMID: 41497097] Laboratory literature summary: Pharmacological progress in metabolic research models: tirzepatide's rising advantage over semaglutide
US$ 20.96
US$ 26.07
US$ 28.82
US$ 29.23
US$ 28.61
US$ 29.32
